跳至主要内容
临床试验/NCT00857597
NCT00857597终止3 期

A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study

University of Pittsburgh1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
60
试验地点
1
主要终点
GERD symptoms

研究概览

简要总结

The study objective is to evaluate the relative merits, safety and effectiveness of Transoral Incisionless Fundoplication (TIF) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-75 years
  • Proven gastroesophageal reflux (pH < 4 for > 4.3% time while off PPIs for 7-14 days)
  • On daily PPIs for > 1 year
  • Recurrence of GERD symptoms (GERD-HRQL score difference of > 10 between on and off PPIs)
  • Normal or hypotonic LES resting pressure (5-40 mmHg)
  • Patient willingness to cooperate with random group assignment, attend 4-5 office visits and comply with all tests in this protocol
  • Signed informed consent

排除标准

  • BMI > 35
  • Hiatal hernia > 2 cm
  • Esophagitis grade D
  • Barrett's esophagus
  • Esophageal stricture
  • Esophageal ulcer
  • Esophageal motility disorder
  • Gastric motility disorder
  • Prior splenectomy
  • Gastric paralysis
  • Pregnancy (in females)
  • Immunosuppression
  • Portal hypertension
  • Coagulation disorders
  • Previous antireflux procedure
  • Any other health condition, which the investigator believes would prevent the patient from completing the study
  • Lack of fluency in English

研究组 & 干预措施

EsophyX

Experimental

干预措施: Transoral Incisionless Fundoplication (Procedure)

Proton Pump Inhibitors

Active Comparator

干预措施: Proton Pump Inhibitors; active control (Drug)

结局指标

主要结局

GERD symptoms

时间窗: 12 month follow-up

次要结局

  • PPI usage(at 0, 6 and 12 month follow- up)
  • Lower esophageal acid exposure(at 0, 6 and 12 month follow- up)
  • Esophagitis(at 0, 6 and 12 month follow- up)
  • Rate of adverse events(at 0, 6 and 12 month follow- up)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验